Market Segmentation:
- By Drug Class
- Riluzole
- Edaravone
- Neuroprotective agents
- Anti-inflammatory drugs
- Others
- By Route of Administration
- Oral
- Intravenous
- Intrathecal
- Subcutaneous
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Pharmacies
- Mail-order Pharmacies
- Others
- By End-User
- Hospitals
- Clinics
- Home Care Settings
- Rehabilitation Centers
- Nursing Homes
- Others
- By Disease Type
- Sporadic ALS
- Familial ALS
- Juvenile ALS
- Bulbar ALS
- Others
- By Mechanism of Action
- Glutamate Release Inhibitors
- Antioxidants
- Anti-inflammatory Agents
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East, and Africa
Frequently Asked Questions
The current market size of the Amyotrophic Lateral Sclerosis (ALS) industry is US$ 630 million.
The increasing prevalence of ALS due to an aging population, advancements in diagnostic techniques, growing research and development efforts, rising awareness and support initiatives, and the development of novel therapies are the key factors driving the growth of the Amyotrophic Lateral Sclerosis (ALS) market.
The high cost of treatment, limited approved therapeutic options, stringent regulatory approval processes, and the lack of disease-modifying therapies are the primary factors hampering the growth of the Amyotrophic Lateral Sclerosis (ALS) market.
The leading component segment in the Amyotrophic Lateral Sclerosis (ALS) Market is the riluzole segment, as it is the only FDA-approved drug for ALS.
The major players operating in the Amyotrophic Lateral Sclerosis (ALS) Market include Mitsubishi Tanabe Pharma Corporation, Biogen Inc., Ionis Pharmaceuticals, Inc., Cytokinetics, Inc., Orion Pharma, Apotex Inc., Sun Pharmaceutical Industries Ltd., and Bausch Health Companies Inc.
The CAGR of the Amyotrophic Lateral Sclerosis (ALS) Market for the forecast period of 2024-2031 is 9.8%, and the market size is expected to reach US$ 1,330.9 million by 2031.
The increasing prevalence of ALS, advancements in diagnostic techniques, growing research and development efforts, rising awareness and support initiatives, and the development of novel therapies are the key drivers of the Amyotrophic Lateral Sclerosis (ALS) Market.